IDEA Collider | Pharma Book Club | Dr Jeremy Levin

IDEA Collider: Innovation & Asymmetric Learning in Pharma

Content provided by IDEA Pharma and SAI MedPartners. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by IDEA Pharma and SAI MedPartners or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

5+ y ago 43:51

MP3•Episode home

Dr. Jeremy M. Levin is Chairman and CEO of Ovid Therapeutics Inc (NASDAQ:OVID), a company whose mission is to bring treatment to patients with rare neurological conditions. Dr. Levin is concurrently the chairman of the Biotechnology Innovation Organization (BIO). Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd., (TLV: TEVA) Before Teva, Dr. Levin was member of the executive committee Bristol-Myers Squibb Company (NYSE: BMY). In that capacity he was the architect of and implemented the String of Pearls Strategy, which transformed Bristol. Dr. Levin joined BMY from Novartis (SWX: NOVN) where he was global head of strategic alliances. He has served on the board of directors of various public and private biopharmaceutical companies and is currently on the board of directors of Lundbeck (OMX: LUN). Dr. Levin was voted as one of the twenty-five most influential biotechnology leaders by Fierce Biotech and one of the top three biotechnology CEOs in 2020 by The Healthcare Technology Report. He is the recipient of the Albert Einstein Award for Leadership in Life Sciences and the B’nai B’rith Award for Distinguished Achievement. He has practiced medicine at university hospitals in England, South Africa, and Switzerland. Dr. Levin earned his bachelor’s degree in zoology and a master’s degree and doctorate in chromatin structure, at the University of Oxford, and thereafter his medical and surgical degrees from the University of Cambridge where he won the Kermode Prize for his work on Captopril.

Authors of individual chapters

HISTORICAL PERSPECTIVES

Vicki L. Sato, Stelios Papadopoulos, Sam Waksal, Bill Sibold, Frederick Frank Q&A with a Biotech Pioneer, Brook Byers, Sol Barer

PERSONAL PERSPECTIVES

Michelle McMurry-Heath, Andy Plump, Kiran Mazumdar-Shaw, Karen Bernstein, Ron Cohen, Samantha Du, Cedric François

THE VIEW FROM INSIDE COMPANIES

George Scangos, John Young, Stéphane Bancel, Jean-Pierre Sommadossi, John V. Oyler, Paul Hastings, Christi Shaw, John Maraganore, Rachel King, Richard Pops, Deborah Dunsire

BROAD LESSONS

Kenneth I. Moch, Quita Highsmith, Luke Rosen, Sylvia Wulf, Philip Miller, Alex Zhavoronkov and Evelyne Bischof

LEADERSHIP

Jeffrey M. Solomon, Julie Louise Gerberding, Jeff Berkowitz, James Greenwood

INVESTOR PERSPECTIVES

Nina Kjellson, Bruce Booth, Alexander Karnal, Mark Lampert, Geoff Porges

LOOKING TO THE FUTURE

Peter Kolchinsky, Yaron Werber, Jeff Kindler, Otello Stampacchia

60 episodes

#Science #MBA #Biology #Business #Marketing #IDEA Pharma #Pharmaceutical Innovations #Author Interviews #Book Club #Book Review #Pharmaceutical #Innovation #Pharma